SciBX: Science-Business eXchange Contents: December 18 2014, Volume 7 / Issue 48

If you are unable to see the message below, click here to view.

Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery   The November 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Aphios Corporation.   TABLE OF CONTENTS December 18 2014, Volume 7 / Issue 48 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Cardiovascular disease Infectious disease Inflammation The Distillery: Techniques Chemistry Drug platforms Markers Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The November 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Sphere Fluidics.    Analysis Cover Story Top Neutralizing the negatives of RNAi Kai-Jye Lou doi:10.1038/scibx.2014.1394 The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside the liver and expand their use to a host of new diseases. Full Text | PDF Translational Notes Top Translational balance C. Simone Fishburn doi:10.1038/scibx.2014.1395 Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference. Full Text | PDF Translational tidbits Simone Fishburn, Kai-Jye Lou and Mark Zipkin doi:10.1038/scibx.2014.1396 Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships. Full Text | PDF Targets and Mechanisms Top Resurrecting a magic bullet Stephen Parmley doi:10.1038/scibx.2014.1397 Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform. Full Text | PDF Tools Top Genocea's mark on malaria Benjamin Boettner doi:10.1038/scibx.2014.1398 Genocea has identified an immunological imprint in patients with malaria and is using a $1.2 million grant from the Gates Foundation to turn the findings into a vaccine. Full Text | PDF Distillery: Therapeutics Cancer Top Estrogen receptor; LYN kinase (LYN); phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2014.1399 Studies in mice and human samples suggest inhibiting LYN could help treat estrogen receptor–positive breast cancers resistant to anti-estrogen therapy. Full Text | PDF Tripartite motif containing 37 (TRIM37) doi:10.1038/scibx.2014.1400 In vitro and mouse studies suggest inhibiting TRIM37 could help treat breast cancer. Full Text | PDF Cyclin dependent kinase 7 (CDK7); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC) doi:10.1038/scibx.2014.1401 In vitro and mouse studies suggest THZ1, a covalent CDK7 inhibitor, could help treat neuroblastoma and other cancers driven by MYCN and other c-MYC (MYC)-family oncoproteins. Full Text | PDF Epidermal growth factor receptor 1 (EGFR1; ErbB1; HER1); HER2 (EGFR2; ErbB2; neu); HER3 (EGFR3; ErbB3); VEGF doi:10.1038/scibx.2014.1402 Tumor cell and mouse studies suggest tetravalent antibodies that target four different antigens could help treat cancers resistant to HER-targeted therapies. Full Text | PDF Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4 doi:10.1038/scibx.2014.1403 Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines. Full Text | PDF Topoisomerase II binding protein 1 (TOPBP1) doi:10.1038/scibx.2014.1404 Mouse and cell culture studies suggest inhibiting TOPBP1 could help treat cancer. Full Text | PDF K-Ras (KRAS) doi:10.1038/scibx.2014.1405 In vitro and mouse studies suggest rapamycin plus a bisphosphonate could help treat KRAS-mutant NSCLC. Full Text | PDF Cardiovascular disease Top Sortilin 1 (SORT1) doi:10.1038/scibx.2014.1406 Mouse studies suggest inhibiting SORT1 in macrophages and T cells could help treat atherosclerosis. Full Text | PDF c-jun N-terminal kinase (JNK); MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1) doi:10.1038/scibx.2014.1407 In vitro and rodent studies suggest ophiopogonin D could help prevent doxorubicin-induced cardiotoxicity. Full Text | PDF Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3) doi:10.1038/scibx.2014.1408 Mouse studies suggest inhibiting PGF could help treat hypertension. Full Text | PDF Glutathione peroxidase 4 (GPX4) doi:10.1038/scibx.2014.1409 Mouse studies suggest inhibiting ferroptosis could help treat ischemia/reperfusion injury in the liver and kidney. Full Text | PDF Infectious disease Top HIV reverse transcriptase doi:10.1038/scibx.2014.1410 In vitro studies have identified indolylarylsulfone derivatives that could help treat HIV infection. Full Text | PDF IgE doi:10.1038/scibx.2014.1411 Mouse studies suggest enhancing persistent IgE responses could help prevent GI infection with parasitic worms. Full Text | PDF Influenza A virus hemagglutinin doi:10.1038/scibx.2014.1412 Cell and mouse studies have identified pentacyclic triterpenoid analogs that could help treat influenza infections and have lower risk for resistance than amantadine. Full Text | PDF VEGF receptor (VEGFR) doi:10.1038/scibx.2014.1413 Zebrafish studies suggest VEGFR inhibitors could help treat tuberculosis. Full Text | PDF Inflammation Top Dermatophagoides pteronyssinus peptidase 1 (DERP1) doi:10.1038/scibx.2014.1414 In vitro and rat studies suggest inhibiting the enzymatic activity of house dust mite (HDM) allergens could help treat allergic asthma. Full Text | PDF Distillery: Techniques Chemistry Top Nanomolar-scale, high throughput chemical synthesis of drug-like molecules doi:10.1038/scibx.2014.1415 A high throughput, miniaturized chemical synthesis platform could enable rapid discovery of lead compounds. Full Text | PDF Drug platforms Top Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent binding to neonatal Fc receptor doi:10.1038/scibx.2014.1416 Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives. Full Text | PDF RNAi against therapeutic targets with short interfering ribonucleic neutrals (siRNNs) doi:10.1038/scibx.2014.1417 siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA. Full Text | PDF Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAs doi:10.1038/scibx.2014.1418 miRNA-targeted antimiRs conjugated to a peptide with a low pH–induced transmembrane structure (pHLIP) could help treat solid tumors. Full Text | PDF Markers Top Chromosome 11 open reading frame 30 (C11orf30), calpain small subunit 1 (CAPNS1; CAPN4), signal transducer and activator of transcription 6 (STAT6) and ankyrin repeat domain 27 (ANKRD27) as diagnostic markers for eosinophilic esophagitis (EoE) doi:10.1038/scibx.2014.1419 Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE. Full Text | PDF MicroRNA let-7c (MIRLET7C; let-7c), miR-99a and miR-125b as prognostic markers of luminal breast cancer doi:10.1038/scibx.2014.1420 Studies in patient samples and cell culture suggest let-7c, miR-99a and miR-125b could serve as prognostic markers in patients with estrogen receptor–positive luminal breast cancers. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.